Weiss, A., Delavenne, E., Matias, C., Lagler, H., Simon, D., Li, P., Hansen, J. U., dos Santos, T. P., Jana, B., Priemel, P., Bangert, C., Bauer, M., Eberl, S., Nussbaumer‐Pröll, A., Anne Österreicher, Z., Matzneller, P., Quint, T., Weber, M., Nielsen, H. M., Rades, T., Johansen, H. K., Westh, H., Kim, W., Mylonakis, E., Friis, C., Guardabassi, L., Pace, J., Lundberg, C. V., M'Zali, F., Butty, P., Sørensen, N., Nielsen, H. B., Toft‐Kehler, R., Guttman‐Yassky, E., Stingl, G., Zeitlinger, M., & Sommer, M. (2022). topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double‐blind, placebo‐controlled Phase 2 trial. Clinical and translational medicine, 12(5), n/a. http://access.bl.uk/ark:/81055/vdc_100156418724.0x000019